



MMJ Group Holdings Limited
Suite 5706, Level 57, MLC Centre
19-29 Martin Place
Sydney NSW Australia 2000

www.mmjgh.com.au
info@mmjgh.com.au

ASX RELEASE

27 August 2021

MMJ Group invests USD1m in Brainworks Inc.

MMJ Group Holdings Limited (ASX: MMJ) ("MMJ") is an Australian-listed specialist investment company which offers the opportunity to invest in a globally diversified portfolio holding investments in private (typically pre-IPO) and public companies in high growth industries. MMJ's current investments are largely minority holdings in Australian and offshore cannabis-related businesses with investments being added in other high growth industries such as but not limited to natural resources, healthcare and software services technology.

MMJ invests USD1m in Brainworks Foundry Inc.

MMJ has completed an investment of USD1m in unlisted Brainworks Foundry Inc. ("**Brainworks**"). MMJ's investment was part of a total pre-IPO equity financing of USD3.7m to fund the expansion of its Medio Labs laboratory testing operations in the United States of America. The investment was made from MMJ's existing cash reserves.

Brainworks is an integrated digital health and pathology company operating in the United States. Medio Labs is a commercial laboratory testing service operated by Brainworks. Medio Labs has designed a best in-breed, highly scalable polymerase chain reaction ("**PCR**") testing process, using DNA barcoding, which significantly reduces the cost and turnaround time of next-generation gene-sequencer analysis for COVID-19 samples. This testing process was first deployed for COVID-19 PCR testing in October 2020 after receiving an Emergency Use Approval from the U.S. FDA.

Brainworks will use the proceeds from the offer to establish their first larger-scale gene sequencing pathology lab in Alameda, California. This will allow Brainworks to service up to 150 markets across the US and provide end-to-end gold-standard PCR COVID testing in under 24 hours. Results will be delivered via the secure Brainworks digital health platform.

"The investment in Brainworks demonstrates MMJ's expertise to secure a private negotiated investment in unlisted businesses which are not generally available to Australian retail and institutional investors, Mr. Wall said. Brainworks represents continued deployment of funds in accordance with its investment strategy following the broadening of MMJ's investment mandate in 2020."

MMJ's investment in Brainworks has an acquisition cost of USD1m and comprises 1,234,568 shares representing approximately 7% of Brainworks' issued capital on completion of the Brainworks USD3.7m capital raising.

Investor and Media Enquiries

Announcement authorised for release to ASX by:
Jim Hallam
Chief Financial Officer and Company Secretary
E: Compsec@mmjgh.com.au

About MMJ

MMJ Group Holdings Limited (ASX:MMJ) ("MMJ") (ABN 91 601 236 417) is an Australian-listed specialist investment company which offers the opportunity to invest in a globally diversified portfolio holding investments in private (typically pre-IPO) and public companies in high growth industries. MMJ's current investments are largely minority holdings in Australian and offshore cannabis-related businesses with investments being added in other high growth industries such as but not limited to natural resources, pharmaceuticals and software services technology.

Important Notice

This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Glossary



ABBREVIATION ^α	Definition ^α
AUD ^α	means Australian dollars. ^α
AA SB ^α	Australian Accounting Standards Board. ^α
ACMPR ^α	means Access to Cannabis for Medical Purposes Regulations. ^α
ASX ^α	means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires. ^α
ASX Listing Rules ^α	means the Listing Rules of ASX. ^α
B2B ^α	Business to business ^α
CAD ^α	means Canadian dollars. ^α
CBD ^α	means Cannabidiol (CBD) is a crystalline, nonintoxicating cannabinoid in cannabis and hemp. ^α
CBG ^α	means Cannabigerol is the non-acidic form of cannabigerolic acid, the parent molecule from which other cannabinoids are synthesized. ^α
Company or MMJ ^α	means MMJ Group Holdings Limited (ACN 601 236 417). ^α
DNA ^α	deoxyribonucleic acid ^α
EBITDA ^α	means Earnings before Interest, Tax, Depreciation and Amortisation. ^α
GMP ^α	GMP stands for Good Manufacturing Practices and refers to a system of manufacturing that guarantees reproducibility of product quality to set specifications. ^α
IPO ^α	Initial public offering of securities on a recognised securities exchange ^α
LPs ^α	Canada's Licensed Producers of Cannabis Products ^α
M ^α	means million ^α
MMPR ^α	means Marihuana for Medical Purposes Regulation ^α
MOIC ^α	means multiple on invested capital ^α
NTA ^α	means net tangible assets. ^α
PCR ^α	polymerase chain reaction ^α
Covid19 ^α	CO stands for corona, 'VI' for virus, and 'D' for disease. ^α
Option ^α	means an option to acquire a Share usually at predetermined price. ^α
Share ^α	means a fully paid ordinary share in the capital of the Company. ^α
Shareholder ^α	means a registered holder of a Share. ^α
TGA ^α	Means the Therapeutic Goods Administration ^α
THC ^α	means THC is the principal psychoactive constituent of cannabis. ^α
TSXV ^α	Toronto Stock Exchange Venture [¶]
Warrant ^α	means an option to acquire a Share usually at predetermined price. ^α
WST ^α	means Western Standard Time as observed in Perth, Western Australia. ^α

¶